Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RotaTeq

- PMLiVE

GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate

There are currently no licensed vaccines offering simultaneous protection against all five serogroups

- PMLiVE

Results for GSK’s RSV vaccine candidate published in New England Journal of Medicine

RSV infections in older adults account for around 6,000 to 10,000 deaths in the US each year

- PMLiVE

GSK and Vir Biotech amend COVID-19 research partnership

Vir will now advance new antibodies and vaccines for COVID-19 alone or with other partners

- PMLiVE

GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis

The rare autoimmune disease affects two to ten people per million and has limited treatments

Video: Strategic engagement case study

Supporting the launch of a global vaccine with a programme of market research and strategic insights

Research Partnership

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

- PMLiVE

GSK’s Jemperli shows promise in phase 3 endometrial cancer trial

An interim analysis noted the trial met its primary endpoint of progression-free survival

- PMLiVE

GSK’s new global survey exposes lupus treatment gaps

The findings show opportunities to address organ damage risk for early stage lupus patients

- PMLiVE

Merck’s Keytruda meets primary endpoint in phase 3 gastric cancer trial

Gastric cancer is the fourth leading cause of cancer death worldwide

- PMLiVE

Merck to acquire Imago BioSciences in deal worth $1.35bn

The agreement includes lead candidate, bomedemstat, for myeloproliferative neoplasms

- PMLiVE

WHO launches R&D efforts to identify pathogens that could cause future pandemics

Over 300 scientists will convene to discuss over 25 virus and bacteria, including ‘Disease X’

- PMLiVE

CDC shows new BQ.1 and BQ 1.1 Omicron subvariants account for 44% of US COVID-19 cases

The two new variants accounted for over 32% of US cases the prior week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links